医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2013年
12期
2353-2355
,共3页
哮喘%白细胞介素13%免疫球蛋白E
哮喘%白細胞介素13%免疫毬蛋白E
효천%백세포개소13%면역구단백E
Asthma%Interleukin-13%Immunoglobulin E
[目的]探讨舒利迭联合孟鲁司特对咳嗽变异性哮喘(CVA)患儿的治疗作用及可能作用机制。[方法]选择80例C V A患儿按数字表法随机分为观察组和对照组,每组40例,观察组给予舒利迭联合孟鲁司特治疗,对照组给予舒利迭治疗,8周后观察两组患儿的临床疗效及治疗前后血清白介素-13(IL-13)、免疫球蛋白E(IgE)的含量变化。[结果]观察组临床总有效率为97.5%、对照组为80.0%,两组临床总有效率比较有统计学差异( P <0.05);治疗后观察组IL-13、Ig E水平及对照组Ig E水平均下降,与本组治疗前比较差异均有统计学意义( P <0.05),且观察组 IL-13与对照组比较差异有显著性( P <0.05);治疗前两组血清IL-13、IgE水平间呈正相关( P<0.05)。[结论]舒利迭联合孟鲁司特对CVA患儿的疗效显著,可调节其外周血IL-13、Ig E的水平变化。
[目的]探討舒利迭聯閤孟魯司特對咳嗽變異性哮喘(CVA)患兒的治療作用及可能作用機製。[方法]選擇80例C V A患兒按數字錶法隨機分為觀察組和對照組,每組40例,觀察組給予舒利迭聯閤孟魯司特治療,對照組給予舒利迭治療,8週後觀察兩組患兒的臨床療效及治療前後血清白介素-13(IL-13)、免疫毬蛋白E(IgE)的含量變化。[結果]觀察組臨床總有效率為97.5%、對照組為80.0%,兩組臨床總有效率比較有統計學差異( P <0.05);治療後觀察組IL-13、Ig E水平及對照組Ig E水平均下降,與本組治療前比較差異均有統計學意義( P <0.05),且觀察組 IL-13與對照組比較差異有顯著性( P <0.05);治療前兩組血清IL-13、IgE水平間呈正相關( P<0.05)。[結論]舒利迭聯閤孟魯司特對CVA患兒的療效顯著,可調節其外週血IL-13、Ig E的水平變化。
[목적]탐토서리질연합맹로사특대해수변이성효천(CVA)환인적치료작용급가능작용궤제。[방법]선택80례C V A환인안수자표법수궤분위관찰조화대조조,매조40례,관찰조급여서리질연합맹로사특치료,대조조급여서리질치료,8주후관찰량조환인적림상료효급치료전후혈청백개소-13(IL-13)、면역구단백E(IgE)적함량변화。[결과]관찰조림상총유효솔위97.5%、대조조위80.0%,량조림상총유효솔비교유통계학차이( P <0.05);치료후관찰조IL-13、Ig E수평급대조조Ig E수평균하강,여본조치료전비교차이균유통계학의의( P <0.05),차관찰조 IL-13여대조조비교차이유현저성( P <0.05);치료전량조혈청IL-13、IgE수평간정정상관( P<0.05)。[결론]서리질연합맹로사특대CVA환인적료효현저,가조절기외주혈IL-13、Ig E적수평변화。
[Objective]To explore the efficacy of seretide combined with montelukast for the treatment of pediat-ric patients with cough variant asthma (CVA ) and the possible action mechanisms .[Methods]Totally 80 CVA pa-tients were randomly divided into observation group and control group with 40 patients in each group .The observation group received seretide combined with montelukast ,while the control group received seretide .After 8 weeks ,clinical efficacy and serum levels of interleukin-13(IL-13) and immunoglobulin E(IgE) of two groups before and after treat-ment were observed .[Results]Clinical total effective rate of observation group was 97 .5% ,while that of control group was 80 .0% .There was significant difference in total clinical efficiency between two groups ( P<0 .05) .After treatment ,IL-13 and IgE in observation group and IgE levels in control group were decreased ,and there was signifi-cant difference between before and after treatment ( P<0 .05) .There was significant difference in IL-13 between ob-servation group and control group( P<0 .05) .Before treatment ,serum IL-13 of two groups were positively correla-ted with IgE( P<0 .05) .[Conclusion]Seretide combined with montelukast for the treatment of CVA has significant efficacy ,and can regulate the changes of IL-13 and IgE in peripheral blood .